Urologic Oncology: Seminars and Original Investigations
Volume 35, Issue 8, August 2017, Pages 536-537
Commentary on “Inherited DNA-repair gene mutations in men with metastatic prostate cancer”. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443–53.
Section snippets
Commentary
As noted in the prior studies discussed, there is a growing interest in the effect of DNA-repair defects to identify candidates for poly-ADP-ribose polymerase inhibitors [1], [2]. Given this, the key question is how often do these defects occur. This article aims to answer that question.
A total 692 men with metastatic prostate cancer and 499 men with localized prostate cancer and 53,105 men without prostate cancer were recruited. All told, the prevalence of germline defects in DNA-repair genes
References (2)
- et al.
DNA-repair defects and prostate cancer
N Engl J Med
(2015) - et al.
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development
J Clin Oncol
(2015)
Cited by (0)
© 2017 Elsevier Inc. All rights reserved.